Periprocedural myocardial infarction: Review and classification

Clinical Cardiology

Volumn 33, Issue 8, 2010, Pages 476-483

  Hanna, Elias B ^a   Hennebry, Thomas A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CREATINE KINASE MB; EPTIFIBATIDE; TROPONIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; CORONARY STENT; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; HUMAN; INCIDENCE; ISCHEMIC PRECONDITIONING; LOADING DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; PROGNOSIS; Q WAVE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC; TIME FACTORS; TROPONIN; UP-REGULATION;

EID: 77955994657     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20819     Document Type: Review

References (53)

1. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
2. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. ESC/ACCF/AHA/WHF Expert Consensus Document. J Am Coll Cardiol. 2007;50:2173-2195.
3. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
4. Giugliano RP, White JA, Boden C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176-2190.
5. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165-2175.
6. Boden WE, O' Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;35:1503-1516.
7. Herrmann J Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493-2519.
8. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes. An analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:477-486.
9. The EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
10. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104:642-647. (Pubitemid 32738516)
11. Srinivas VS, Brooks MM, Detre KM, et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation. 2002;106:1627-1633.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2006;113:e166-e286.
13. Brenner SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 2002;40:1961-1967.
14. Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J. 2004;25:313-321.
15. Ioannidis JPA, Karvouni E, Katritsis DG, et al. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411. (Pubitemid 37267281)
16. Linefsky JP, Lin M, Pieper KS, et al. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the International Trial SYNERGY). Am J Cardiol. 2009;104:1330-1335.
17. Feldman DN, Minutello RM, Bergman G, et al. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short-and long-term outcomes. Am J Cardiol. 2009;104:1210-1215.
18. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005;111:1027-1032.
19. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol. 1999;84:51-57.
20. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-1082.
21. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738-1744.
22. Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-1498. (Pubitemid 41373489)
23. Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008;1:10-19.
24. Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol. 2006;48:1765-1770. (Pubitemid 44648624)
25. Jeremias A, Kutscher S, Haude M, et al. Nonischemic chest pain induced by coronary interventions: a prospective study comparing coronary angioplasty and stent implantation. Circulation. 1998;98:2656-2658.
26. Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol. 2003;41:33-38. (Pubitemid 36044400)
27. Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation. 2000;101:604-610.
28. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348-353. (Pubitemid 29051259)
29. Baim DS, Wahr D, George B, et al; Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts. Circulation. 2002;105:1285-1290.
30. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100:2400-2405.
31. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease - a randomized controlled trial. JAMA. 2005;294:1215-1223.
32. Dawkins KD, Grube E, Guagliumi G, et al. Taxus VI Investigators Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-3313.
33. Chu WW, Kuchulakanti PK, Torguson R, et al. Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;67:595-599.
34. Kereiakes D, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping cypher sirolimus-eluting stents. Pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48:21-31.
35. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106:1205-1210. (Pubitemid 34988637)
36. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006;47:939-943.
37. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet. 2001;358:527-533.
38. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2005;112:2946-2950.
39. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
40. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531-1538.
41. Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel With Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol. 2009;53:648-657.
42. Kastrati A, Mehilli J, Schuhlen H, et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl JMed. 2004;350:232-238.
43. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106:3063-3067. (Pubitemid 35440289)
44. Brigori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009;54:2157-2163.
45. Patti G, Colonna G, Pasceri V, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278.
46. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol. 2009;54:558-565.
47. Gurm HS, Breibart Y, Vivekanathan D, et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy - a propensityadjusted analysis. Am Heart J. 2006;151:1031-1036.
48. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. A randomized controlled trial (EMERALD trial). JAMA. 2005;293:1063-1072.
49. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007;50:1442-1449. (Pubitemid 47494591)
50. Laskey WK Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation. 1999;99:2085-2089.
51. Laskey WK, Beach D Frequency and clinical significance of ischemic preconditioning during percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1004-1006.
52. Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002;106:2881-2883.
53. Hoole SP, Heck PM, Sharples L, et al. Cardiac remote ischemic preconditioning in coronary stenting (CRISP Stent) study. Circulation. 2009;119:820-827.